GHK-Cu Geriatric (65+) Safety: What Older Adults and Their Clinicians Need to Know

Print or save as PDF

Is any GHK-Cu product FDA-approved?

No. FDA treats GHK-Cu as a nominated bulk drug substance, not an approved medicine [1]. It is not copper histidinate (Zycubo), which FDA approved on January 12, 2026 for Menkes disease in children [6].

The topical and injectable forms are regulated differently. Copper peptide serums and creams are sold as cosmetics, and cosmetics other than color additives do not need FDA approval before sale; a product claiming to treat disease or to change the structure or function of the body would legally be a drug [5]. An injectable GHK-Cu product is not a cosmetic and is not FDA-approved [5].

FDA's list of bulk substances for state-licensed pharmacies and physicians places 'GHK-Cu (except for injectable routes of administration)' in category 1, the group still under evaluation for the bulks list [1][7]. The injectable form appears instead in FDA's nominated-but-withdrawn table [4][1]. FDA has said it intends to consult its Pharmacy Compounding Advisory Committee about GHK-Cu before the end of February 2027; no vote has taken place [1]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [8].

What do the human trials show?

Both randomized trials found for GHK-Cu tested topical creams, and both were small. In a venous stasis ulcer trial, 86 evaluable patients received a 0.4% tripeptide copper complex cream, silver sulfadiazine 1%, or an inert vehicle; the copper cream was no different from placebo on ulcer size, while silver sulfadiazine reduced it [2]. In a laser-resurfacing trial, 13 patients completed post-treatment skin care with or without GHK-Cu; computer analysis and blinded evaluators found no significant difference in redness resolution or wrinkles, while a patient questionnaire showed a significant difference in overall skin quality favoring GHK-Cu (P=.04) [3].

A 2026 systematic review retained 64 records from a search covering 2005 to 2026 and concluded that, despite four decades of preclinical work, the human literature is thin and fragmented: most randomized trials are small, use facial cosmetic creams, and microneedle delivery has not been tested in an adequately powered registered human trial [9].

Does aging change how the body handles copper?

GHK levels in human plasma, saliva and urine are reported to decline with age, and its proposers suggest it works as a complex with copper [10]. We found no study that measured how GHK-Cu is handled in older adults, or that tracked serum copper in people using a copper peptide cream or an unapproved injection.

What FDA says about injectable GHK-Cu safety

For injectable GHK-Cu, FDA says compounded injectable drugs containing GHK-Cu may pose a risk for immunogenicity due to the potential for aggregation and peptide-related impurities, and that there are limited data in humans to inform safety-related considerations [4]. FDA cites limited human safety data, and no adverse-event rates were found in the trials checked.

The randomized human trials found used topical creams, and no adverse-event rates were found in their reports [2][3]. Topical copper peptide products are sold as cosmetics, which need no FDA approval before sale [5].